clinical trial · NCT06961370
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Hoffmann-La Roche·phase1·recruiting·n = 132
Geographic AtrophyAge-related Macular DegenerationRO7669330Syfovre™Izervay™
brief summary
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.
started
Jul 16, 2025
primary completion
Jan 3, 2027
completion
Jan 3, 2027
last updated
Apr 3, 2026
official title
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol